JP Morgan Chase
CTXR icon

JP Morgan Chase’s Citius Pharmaceuticals CTXR Stock Holding History

JP Morgan Chase’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82 Hold
120
– – ﹤0.01% 7323
2025
Q4 		$93 Hold
120
– – ﹤0.01% 7219
2025
Q3 		$149 Hold
120
– – ﹤0.01% 7141
2025
Q2 		$191 Sell
120
-16
-12% -$15 ﹤0.01% 6785
2025
Q1 		$203 Buy
136
+12
+10% +$29 ﹤0.01% 6797
2024
Q4 		$496 Buy
124
+2
+2% +$13 ﹤0.01% 6802
2024
Q3 		$1.52K Hold
122
– – ﹤0.01% 6665
2024
Q2 		$1.77K Sell
122
-1,927
-94% -$34.5K ﹤0.01% 6546
2024
Q1 		$46K Sell
2,049
-1,141
-36% -$20.8K ﹤0.01% 5983
2023
Q4 		$60.3K Hold
3,190
– – ﹤0.01% 5939
2023
Q3 		$54.6K Sell
3,190
-731
-19% -$17.4K ﹤0.01% 5774
2023
Q2 		$118K Buy
3,921
+3,918
+130,600% +$129K ﹤0.01% 5389
2023
Q1 		$0 Hold
3
– – ﹤0.01% 6775
2022
Q4 		$0 Hold
3
– – ﹤0.01% 6610
2022
Q3 		$0 Hold
3
– – ﹤0.01% 6510
2022
Q2 		$0 Sell
3
-2,325
-100% -$63.7K ﹤0.01% 6523
2022
Q1 		$104K Buy
2,328
+581
+33% +$22.9K ﹤0.01% 5488
2021
Q4 		$67K Sell
1,747
-1,828
-51% -$82.9K ﹤0.01% 5839
2021
Q3 		$181K Sell
3,575
-2,568
-42% -$129K ﹤0.01% 5289
2021
Q2 		$535K Buy
+6,143
New +$369K ﹤0.01% 4649

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

JP Morgan Chase's CTXR Position: Q1 2026 in Review

JP Morgan Chase held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 120 shares worth $82. The position accounts for ﹤0.01% of the portfolio, ranked #7323.

JP Morgan Chase first reported a position in CTXR in Q2 2021 and has held it in 20 quarters since. The position peaked at $535K in Q2 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • JP Morgan Chase held 120 shares of Citius Pharmaceuticals worth $82 as of Q1 2026.
  • JP Morgan Chase left its Citius Pharmaceuticals share count unchanged in Q1 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7323 holding.
  • JP Morgan Chase first reported a position in Citius Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Citius Pharmaceuticals position peaked at $535K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.